Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

기사 요약

Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full details on earnings and 2026 outlook.